Literature DB >> 20816934

Relationship between blood glucose levels and hepatic Fto mRNA expression in mice.

Nicole J Poritsanos1, Pei San Lew, Tooru M Mizuno.   

Abstract

Common variants in the fat mass and obesity associated (FTO) gene are associated with obesity and type 2 diabetes. Fto-deficient mice develop hepatic insulin resistance, leading to the hypothesis that hepatic Fto plays a role in the regulation of glucose metabolism and that hepatic Fto expression is regulated by metabolic states. We found that hepatic Fto mRNA levels were increased by fasting in mice. Intraperitoneal glucose injection reduced hepatic Fto mRNA levels without significant changes in body weight in fasted mice. The inverse correlation between Fto mRNA and glucose remained significant after adjusting for body weight. There were positive correlations between hepatic Fto mRNA expression and gluconeogenic gene expression. These data support the hypothesis that hepatic Fto expression changes in response to metabolic states and glucose reduces hepatic Fto mRNA expression independently of body weight. Hepatic Fto may participate in the feedback regulation of glucose metabolism via gluconeogenesis.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20816934     DOI: 10.1016/j.bbrc.2010.08.133

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

1.  Is FTO a type 2 diabetes susceptibility gene?

Authors:  D Meyre
Journal:  Diabetologia       Date:  2012-04       Impact factor: 10.122

Review 2.  Emerging role of m6 A RNA methylation in nutritional physiology and metabolism.

Authors:  Jiamin Wu; Katya Frazier; Jingfei Zhang; Zhending Gan; Tian Wang; Xiang Zhong
Journal:  Obes Rev       Date:  2019-09-02       Impact factor: 9.213

3.  Regulation of Activating Transcription Factor 4 (ATF4) Expression by Fat Mass and Obesity-Associated (FTO) in Mouse Hepatocyte Cells.

Authors:  T M Mizuno; P S Lew
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Apr-Jun       Impact factor: 0.877

Review 4.  FTO and obesity: mechanisms of association.

Authors:  Xu Zhao; Ying Yang; Bao-Fa Sun; Yong-Liang Zhao; Yun-Gui Yang
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

5.  Early hypothalamic FTO overexpression in response to maternal obesity--potential contribution to postweaning hyperphagia.

Authors:  Vanni Caruso; Hui Chen; Margaret J Morris
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240

6.  FTO, type 2 diabetes, and weight gain throughout adult life: a meta-analysis of 41,504 subjects from the Scandinavian HUNT, MDC, and MPP studies.

Authors:  Jens K Hertel; Stefan Johansson; Emily Sonestedt; Anna Jonsson; Rolv T Lie; Carl G P Platou; Peter M Nilsson; Gull Rukh; Kristian Midthjell; Kristian Hveem; Olle Melander; Leif Groop; Valeriya Lyssenko; Anders Molven; Marju Orho-Melander; Pål R Njølstad
Journal:  Diabetes       Date:  2011-03-11       Impact factor: 9.461

7.  Knockdown of the fat mass and obesity gene disrupts cellular energy balance in a cell-type specific manner.

Authors:  Ryan T Pitman; Jason T Fong; Penny Billman; Neelu Puri
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

8.  FTO contributes to hepatic metabolism regulation through regulation of leptin action and STAT3 signalling in liver.

Authors:  Amélie Bravard; Guillaume Vial; Marie-Agnès Chauvin; Yves Rouillé; Bernard Bailleul; Hubert Vidal; Jennifer Rieusset
Journal:  Cell Commun Signal       Date:  2014-01-10       Impact factor: 5.712

9.  Impaired hypothalamic Fto expression in response to fasting and glucose in obese mice.

Authors:  N J Poritsanos; P S Lew; J Fischer; C V Mobbs; J I Nagy; D Wong; U Rüther; T M Mizuno
Journal:  Nutr Diabetes       Date:  2011-10-31       Impact factor: 5.097

10.  Expression of miR-33 from an SREBF2 intron targets the FTO gene in the chicken.

Authors:  Fang Shao; Xingguo Wang; Jianfeng Yu; Honglin Jiang; Bin Zhu; Zhiliang Gu
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.